Patients with rheumatic heart disease can generally survive for a longer period of time with regular and effective treatment at an early stage; if the treatment is not timely and standardized, the survival time will be shorter. Rheumatic heart disease is a relatively common heart disease that easily damages the patient’s heart valves, resulting in valvular closure insufficiency or stenosis, thus affecting the heart’s ejection of blood and function. In the early stage, the degree of damage to the patient’s valves is light, the number of damaged valves is small, there may be no obvious discomfort, aspirin, glucocorticoids, diuretics and other medications can be relieved, and can survive for a longer period of time; with the progression of the disease, it can be aggravated by the emergence of heart failure, and in severe cases, sudden death can occur, and the survival time is correspondingly shorter. It is recommended that patients actively cooperate with doctors to standardize the treatment, regular review, and avoid blindly using drugs on their own.